decisionhealth Newsletters, Part B News - 2014 Issue 3 (March)
Expanded coverage for oral drugs used with chemotherapy may shift billing
Subscribe or sign in to view the full article.
Article Overview
This article covers a CMS update expanding coverage for an oral antiemetic regimen associated with chemotherapy, including the affected chemotherapy agents, claims-processing timing, and how the policy may affect billing and payment responsibilities. It is relevant for oncology practices, billing staff, and coders who work with Medicare claims, drug billing, and chemotherapy-related supportive care.
Why This Topic Matters
The coverage change can affect where payment is made for oral supportive drugs, how claims are submitted or reprocessed, and which chemotherapy encounters qualify for reimbursement. Practices need to understand the policy scope to manage billing workflow, payer responsibility, and Medicare claim accuracy.
Article Sections
-
Billing
Overview of the coverage update and its potential effect on billing and payment. Discusses the general context for the oral antiemetic regimen and related practice-level considerations.
What You Will Learn
- What CMS changed regarding coverage for an oral antiemetic regimen used with chemotherapy
- Which general categories of chemotherapy drugs are included in the expanded coverage
- How the update affects claims processing and billing workflow
- Which claim timing and diagnosis context are discussed in the policy update
Who Should Read This
- Oncology practices
- Medical billers
- Professional coders
- Revenue cycle staff
- Hematology/oncology clinicians
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com